The final overall survival (OS) results of the FLAURA2 trial support osimertinib plus chemotherapy as the new first-line standard of care for EGFR-mutated non-small cell lung cancer (NSCLC), according ...
Data from the COMPEL trial support extending osimertinib (Tagrisso, AstraZeneca) therapy to patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who progress on first-line treatment ...
A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients live ...
ASCENT-04 randomized PD-L1–positive, untreated mTNBC to sacituzumab govitecan–pembrolizumab versus chemo–pembrolizumab, yielding a 3.4-month median PFS improvement (HR 0.65). Front-loading an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results